CLAIMS

1. Use of an anti-C5 antibody in the manufacture of a medicament for treating or preventing a C5-related disease in a subject, wherein:
   (a) a loading dose of 1000 mg of the anti-C5 antibody is to be intravenously administered to the subject once, followed by at least one loading dose of 340 mg of the anti-C5 antibody to be subcutaneously administered to the subject; and
   (b) at least one maintenance dose of 680 mg of the anti-C5 antibody is to be subcutaneously administered to the subject.

2. The use according to claim 1, wherein the loading dose of 340 mg of the antibody to be subcutaneously administered is to be administered at least once to the subject 1 day to 3 weeks after the start of the intravenous administration of the anti-C5 antibody.

3. The use according to claim 2, wherein the loading dose of 340 mg of the antibody to be subcutaneously administered is to be administered once to the subject 1 day after the start of the intravenous administration of the anti-C5 antibody.

4. The use according to claim 2 or claim 3, wherein at least one additional loading dose of 340 mg of the anti-C5 antibody is to be subcutaneously administered to the subject 1 week or 2 weeks after the start of the intravenous administration of the anti-C5 antibody.

5. The use according to any one of claims 2 to 4, wherein an additional loading dose of 340 mg of the anti-C5 antibody is to be subcutaneously administered to the subject 1 week and 2 weeks after the start of the intravenous administration of the anti-C5 antibody once weekly.

6. The use according to any one of claims 1 to 4, wherein at least one maintenance dose of 680 mg of the anti-C5 antibody is to be subcutaneously administered to the

subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody.

7. The use according to claim 6, wherein the maintenance dose of 680 mg of the anti-C5 antibody is to be subcutaneously administered once to the subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody.

8. The use according to claim 6 or claim 7, wherein the maintenance dose of 680 mg of the anti-C5 antibody is to be subcutaneously administered to the subject several times with time intervals of at least 4 weeks.

9. The use according to any one of claims 1 to 8, wherein:
   (i) a loading dose of 1000 mg of the anti-C5 antibody is to be intravenously administered to the subject once;
   (ii) a loading dose of 340 mg of the anti-C5 antibody is to be subcutaneously administered to the subject 1 day after the start of the intravenous administration of the anti-C5 antibody;
   (iii) a loading dose of 340 mg of the anti-C5 antibody is to be subcutaneously administered to the subject 1 week, 2 weeks and 3 weeks after the start of the intravenous administration of the anti-C5 antibody once weekly;
   (iv) a maintenance dose of 680 mg of the anti-C5 antibody is to be subcutaneously administered to the subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody; and
   (v) step (iv) is to be repeated several times with time intervals of 4 weeks.

10. The use according to any one of claims 1 to 9, wherein the subject had received prior treatment with at least one pharmacological product useful for the treatment or prevention of the C5-related disease, wherein the loading dose of 1000 mg of the anti-C5 antibody to be intravenously administered is to be administered to the subject after the final dose of the pharmacological product.

11. The use according to claim 10, wherein the loading dose of 1000 mg of the anti-C5 antibody to be intravenously administered is to be administered to the subject on

the third day or after 3 days after administration of the final dose of the pharmacological product.

12. The use according to claim 10 or claim 11, wherein the pharmacological product comprises an siRNA targeting C5 mRNA, or an anti-C5 antibody which is different from the anti-C5 antibody comprised in the composition for subcutaneous or intravenous injection.

13. The use according to any one of claims 10 to 12, wherein the pharmacological product comprises Eculizumab, Ravulizumab or variants thereof.

14. The use according to any one of claims 1 to 13, wherein the subject has a body weight between 40 kg and 100 kg.

15. The use according to any one of claims 1 to 14, wherein the anti-C5 antibody concentration that had been determined in a biological sample of said subject is 100 µg/ml or more.

16. The use according to any one of claims 1 to 14, wherein the hemolytic activity that had been determined in a biological sample of said subject is less than 10 U/mL.

17. The use according to claim 15 or claim 16, wherein the biological sample is a blood sample, preferably a red-blood sample.

18. The use according to any one of claims 1 to 17, wherein the anti-C5 antibody is Crovalimab.

19. The use according to any one of claims 1 to 18, wherein the C5-related disease is selected from a group consisting of paroxysmal nocturnal hemoglobinuria (PNH), rheumatoid arthritis (RA), lupus nephritis, ischemia-reperfusion injury, atypical hemolytic uremic syndrome (aHUS), dense deposit disease (DDD), macular degeneration, hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, thrombotic thrombocytopenic purpura (TTP), spontaneous fetal loss, Pauci-immune vasculitis, epidermolysis bullosa, recurrent fetal loss, multiple sclerosis

(MS), traumatic brain injury, an injury resulting from myocardial infarction, cardiopulmonary bypass or hemodialysis, refractory generalized myasthenia gravis (gMG), and neuromyelitis optica (NMO).